Agenus (AGEN)
(Delayed Data from NSDQ)
$5.84 USD
-0.15 (-2.50%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.87 +0.03 (0.51%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
AGEN 5.84 -0.15(-2.50%)
Will AGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGEN
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Other News for AGEN
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus presents data on botensilimab/balstilimab clinical responses
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024